Endocannabinoid system modulation therapy represents a comprehensive therapeutic approach targeting the endogenous cannabinoid signaling system for treating neurodegenerative diseases. This modality encompasses multiple intervention points including cannabinoid receptors (CB1R, CB2R), endocannabinoid degrading enzymes (FAAH, MAGL), and endocannabinoid transporters, offering neuroprotection through anti-inflammatory, anti-excitotoxic, antioxidant, and neurotrophic mechanisms across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and frontotemporal dementia (FTD). [1]
The endocannabinoid system (ECS) is a ubiquitous lipid-based neuromodulatory system comprising cannabinoid receptors, endogenous lipid ligands (endocannabinoids), and enzymatic machinery for their synthesis and degradation. This system plays fundamental roles in synaptic transmission, neuroinflammation regulation, oxidative stress response, and neuronal survival throughout the central nervous system. [2]
| Target | Function | Therapeutic Modulation |
|---|---|---|
| CB1 Receptor | Retrograde synaptic signaling, neurotransmitter release inhibition | Agonists (neuroprotection), PAMs (enhance signaling) |
| CB2 Receptor | Immunomodulation, inflammation resolution | Agonists (anti-inflammatory) |
| FAAH | Degrades anandamide (AEA) | Inhibitors (elevate AEA tone) |
| MAGL | Degrades 2-arachidonoylglycerol (2-AG) | Inhibitors (elevate 2-AG tone) |
| ABHD6 | Postsynaptic 2-AG degradation | Inhibitors (complementary to MAGL) |
| Endocannabinoid Transporters | Cellular uptake of AEA/2-AG | Reuptake inhibitors |
Anandamide (AEA) is a partial agonist at CB1R and CB2R with high affinity (Ki ~60-90 nM) that also activates TRPV1 channels and PPARγ nuclear receptors. AEA is rapidly degraded by fatty acid amide hydrolase (FAAH), limiting its half-life to approximately 5-10 minutes in vivo.
2-Arachidonoylglycerol (2-AG) is the most abundant endocannabinoid in the brain (~1000× higher concentrations than AEA) and serves as a full agonist at both CB1R and CB2R. 2-AG is primarily degraded by monoacylglycerol lipase (MAGL), which accounts for approximately 85% of 2-AG hydrolysis. [3]
CB1 receptor activation provides neuroprotection through multiple interconnected pathways [2:1]:
CB2 receptor activation represents the primary anti-inflammatory mechanism relevant to neurodegeneration [4]:
FAAH (fatty acid amide hydrolase) inhibition elevates endogenous anandamide levels without direct receptor activation, providing neuroprotection while avoiding the psychoactivity associated with direct CB1R agonists. Key compounds include:
MAGL (monoacylglycerol lipase) inhibition offers dual therapeutic benefits by simultaneously elevating 2-AG (neuroprotective) while reducing arachidonic acid (pro-inflammatory prostaglandin precursor) [5]:
In Alzheimer's disease, ECS dysregulation is extensive and progressive [6]:
The ECS is intimately connected to basal ganglia circuitry and dopaminergic neurodegeneration [7]:
In ALS, both CB1R and CB2R agonists demonstrate neuroprotective effects [8]:
HD shows the most dramatic ECS changes among neurodegenerative conditions [9]:
Emerging evidence suggests ECS dysregulation in FTD:
Rationale: Achieve anti-inflammatory neuroprotection without CB1R-associated psychoactivity
| Compound | Selectivity | Status | Key Evidence |
|---|---|---|---|
| JWH-133 | CB2 > 100x | Preclinical | Reduces Aβ toxicity in AD models |
| HU-308 | CB2 selective | Preclinical | Protects dopaminergic neurons in PD models |
| GW405833 | CB2 partial agonist | Preclinical | Reduces EAE neuroinflammation |
| Lenabasum (JBT-101) | CB2 agonist | Phase II/III | Approved for systemic sclerosis |
Rationale: Elevate both AEA and 2-AG simultaneously for comprehensive endocannabinoid tone restoration [10]
| Compound | Target | Status | Indication |
|---|---|---|---|
| Dual FAAH/MAGL inhibitor | FAAH + MAGL | Phase I | Agitation in AD (NCT06808984) |
| JZL184 | MAGL | Preclinical | AD, PD models |
| URB597 | FAAH | Preclinical | AD, PD models |
Rationale: Enhance endocannabinoid signaling without directly activating the receptor [11]
Rationale: Target peripheral CB2 to avoid CNS-related psychoactivity while modulating systemic inflammation
Rationale: FAAH-sparing approach to restore anandamide tone without hepatotoxicity risks
| Trial ID | Compound | Phase | Indication | Status |
|---|---|---|---|---|
| NCT07142044 | EC5026 (FAAH-i) | I | Parkinson's Disease | Completed |
| NCT05676077 | CBD/THC (Sativex) | II | Alzheimer's Disease | Recruiting |
| NCT06808984 | FAAH/MAGL dual | I | AD Agitation | Ongoing |
| Compound | Indication | Phase | Key Findings |
|---|---|---|---|
| Epidiolex (CBD) | AD | II | Safe, trend toward cognitive benefit |
| Nabilone | PD | II | Improved tremor and dyskinesias |
| Dronabinol | PD | II | Reduced levodopa-induced dyskinesias |
| Approach | Dose Range | Mechanism |
|---|---|---|
| Low-dose CBD | 20-100 mg/day | Anti-inflammatory without psychotropic effects |
| FAAH inhibition | Based on IC50 | Elevate endogenous AEA |
| MAGL inhibition | Based on IC50 | Elevate endogenous 2-AG |
| CB2-selective | Variable | Peripheral anti-inflammatory |
| Disease | Primary Target | Secondary Target | Approach |
|---|---|---|---|
| AD | CB2 (inflammation) | FAAH (AEA tone) | CB2 agonist + FAAH inhibitor |
| PD | CB2 (neuroprotection) | CB1 (dyskinesia) | CB2 agonist + CB1 antagonist |
| ALS | CB2 (microglia) | FAAH (neuroprotection) | Dual approach |
| HD | CB2 (inflammation) | CB1 (early tone) | CB2 agonist |
| FTD | CB2 (inflammation) | Autophagy | CB2 + FAAH/MAGL |
Endocannabinoid signaling in neurodegeneration: new therapeutic perspectives. 2024. ↩︎
Cannabinoids and the expanded endocannabinoid system in neurological disorders. 2020. ↩︎ ↩︎
Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. 2012. ↩︎
CB2 receptor agonists for neurodegenerative disease: from promise to proof. 2023. ↩︎
MAGL inhibition as a dual therapeutic strategy in Alzheimer's disease. 2024. ↩︎
Potential therapeutic targets to modulate the endocannabinoid system in Alzheimer's disease. 2024. ↩︎
Homeostatic changes of the endocannabinoid system in Parkinson's disease. 2011. ↩︎
Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1G93A transgenic mice. 2014. ↩︎
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. 2011. ↩︎
FAAH inhibitors for neurodegenerative disease: beyond pain. 2023. ↩︎
CB1 receptor allosteric modulators: a new class of cannabinoid-based therapeutics. 2019. ↩︎